当科大学院生：數井翔、助教：竹中秀、准教授：永井利幸の原著論文がInternational Journal of Cardiologyに掲載されました
2023.08.17
論文掲載
当科大学院生：數井翔、助教：竹中秀、准教授：永井利幸の原著論文がInternational Journal of Cardiologyに掲載されました。
Kazui, Sho; Takenaka, Sakae; Nagai, Toshiyuki; Kato, Yoshiya; Komoriyama, Hirokazu; Kobayashi, Yuta; Takahashi, Akinori; Kamiya, Kiwamu; Sato, Takuma; Tada, Atsushi; Yasui, Yutaro; Nakai, Michikazu; Sato, Takahiro; Tsujino, Ichizo; Konno, Satoshi; Anzai, Toshihisa
Association of longitudinal cardiac troponin trajectory with adverse events in patients with cardiac sarcoidosis Journal Article
In: International Journal of Cardiology, vol. 389, pp. 131268, 2023, ISSN: 0167-5273.
@article{KAZUI2023131268,
title = {Association of longitudinal cardiac troponin trajectory with adverse events in patients with cardiac sarcoidosis},
author = {Sho Kazui and Sakae Takenaka and Toshiyuki Nagai and Yoshiya Kato and Hirokazu Komoriyama and Yuta Kobayashi and Akinori Takahashi and Kiwamu Kamiya and Takuma Sato and Atsushi Tada and Yutaro Yasui and Michikazu Nakai and Takahiro Sato and Ichizo Tsujino and Satoshi Konno and Toshihisa Anzai},
url = {https://www.sciencedirect.com/science/article/pii/S0167527323011464},
doi = {https://doi.org/10.1016/j.ijcard.2023.131268},
issn = {0167-5273},
year = {2023},
date = {2023-01-01},
urldate = {2023-01-01},
journal = {International Journal of Cardiology},
volume = {389},
pages = {131268},
abstract = {Background
Although high-sensitivity cardiac troponins may be sensitive and easily repeatable markers of disease activity in patients with cardiac sarcoidosis (CS), the association between longitudinal cardiac troponin trajectory and adverse events remains unclear. This study aimed to clarify whether longitudinal cardiac troponin levels were associated with adverse events in patients with CS.
Methods
We examined 63 consecutive CS-initiated prednisolone (PSL) patients with available longitudinal high-sensitivity cardiac troponin T (cTnT) data between December 2013 and March 2023. The area under the cTnT trajectory, which reflected cumulative cTnT release, was calculated to assess the association between longitudinal cTnT levels and adverse events. Patients were divided into two groups according to the median area under the cTnT trajectory per month. The primary outcome was a composite of sustained ventricular tachycardia or fibrillation, worsening heart failure, and sudden cardiac death (SCD).
Results In total, 463 cTnT measurements were collected over a median follow-up period of 30.4 (interquartile range [IQR] 15.6–34.2) months. The primary outcome was observed in 12 (19%) patients. A higher area under the cTnT trajectory was significantly associated with an increased incidence of the primary outcome (P = 0.027), while cTnT levels before and one month after initiation of PSL, and these changes were not related to adverse events (P = 0.179, 0.096, and 0.95, respectively).
Conclusions
Longitudinal cTnT trajectory following PSL initiation was associated with adverse cardiac events in patients with CS, suggesting that longitudinal measurement of cTnT would be useful for the early identification of high-risk patients.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Background
Although high-sensitivity cardiac troponins may be sensitive and easily repeatable markers of disease activity in patients with cardiac sarcoidosis (CS), the association between longitudinal cardiac troponin trajectory and adverse events remains unclear. This study aimed to clarify whether longitudinal cardiac troponin levels were associated with adverse events in patients with CS.
Methods
We examined 63 consecutive CS-initiated prednisolone (PSL) patients with available longitudinal high-sensitivity cardiac troponin T (cTnT) data between December 2013 and March 2023. The area under the cTnT trajectory, which reflected cumulative cTnT release, was calculated to assess the association between longitudinal cTnT levels and adverse events. Patients were divided into two groups according to the median area under the cTnT trajectory per month. The primary outcome was a composite of sustained ventricular tachycardia or fibrillation, worsening heart failure, and sudden cardiac death (SCD).
Results In total, 463 cTnT measurements were collected over a median follow-up period of 30.4 (interquartile range [IQR] 15.6–34.2) months. The primary outcome was observed in 12 (19%) patients. A higher area under the cTnT trajectory was significantly associated with an increased incidence of the primary outcome (P = 0.027), while cTnT levels before and one month after initiation of PSL, and these changes were not related to adverse events (P = 0.179, 0.096, and 0.95, respectively).
Conclusions
Longitudinal cTnT trajectory following PSL initiation was associated with adverse cardiac events in patients with CS, suggesting that longitudinal measurement of cTnT would be useful for the early identification of high-risk patients.
Although high-sensitivity cardiac troponins may be sensitive and easily repeatable markers of disease activity in patients with cardiac sarcoidosis (CS), the association between longitudinal cardiac troponin trajectory and adverse events remains unclear. This study aimed to clarify whether longitudinal cardiac troponin levels were associated with adverse events in patients with CS.
Methods
We examined 63 consecutive CS-initiated prednisolone (PSL) patients with available longitudinal high-sensitivity cardiac troponin T (cTnT) data between December 2013 and March 2023. The area under the cTnT trajectory, which reflected cumulative cTnT release, was calculated to assess the association between longitudinal cTnT levels and adverse events. Patients were divided into two groups according to the median area under the cTnT trajectory per month. The primary outcome was a composite of sustained ventricular tachycardia or fibrillation, worsening heart failure, and sudden cardiac death (SCD).
Results In total, 463 cTnT measurements were collected over a median follow-up period of 30.4 (interquartile range [IQR] 15.6–34.2) months. The primary outcome was observed in 12 (19%) patients. A higher area under the cTnT trajectory was significantly associated with an increased incidence of the primary outcome (P = 0.027), while cTnT levels before and one month after initiation of PSL, and these changes were not related to adverse events (P = 0.179, 0.096, and 0.95, respectively).
Conclusions
Longitudinal cTnT trajectory following PSL initiation was associated with adverse cardiac events in patients with CS, suggesting that longitudinal measurement of cTnT would be useful for the early identification of high-risk patients.